scholarly journals A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology

2019 ◽  
Vol 19 (2) ◽  
pp. 89-96 ◽  
Author(s):  
Arti Hurria ◽  
Enrique Soto-Perez-de-Celis ◽  
Suzette Blanchard ◽  
Peggy Burhenn ◽  
Christina Haeyoung Yeon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Older Adults ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Breast

Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor–Positive, Metastatic Carcinoma of the Breast in Premenopausal Women

2010 ◽  
Vol 28 (25) ◽  
pp. 3917-3921 ◽  
Author(s):  
Robert. W. Carlson ◽  
Richard Theriault ◽  
Christine M. Schurman ◽  
Edgardo Rivera ◽  
Cathie T. Chung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Antitumor Activity ◽  
Phase Ii ◽  
Hormone Receptor ◽  
Phase Ii Trial ◽  
Hot Flashes ◽  
Metastatic Breast ◽  
Premenopausal Women ◽  
Hormone Receptor Positive

Purpose To explore the antitumor activity of the aromatase inhibitor, anastrozole, in the treatment of premenopausal women with hormone receptor–positive, metastatic breast cancer who have been rendered functionally postmenopausal with the use of the luteinizing hormone-releasing hormone agonist, goserelin. Patients and Methods Premenopausal women with estrogen and/or progesterone receptor–positive, metastatic or recurrent breast cancer were enrolled in this prospective, single-arm, multicenter phase II trial. Patients were treated with goserelin 3.6 mg subcutaneous monthly and began anastrozole 1-mg daily 21 days after the first injection of goserelin. Patients continued on treatment until disease progression or unacceptable toxicity. Results Thirty-five patients were enrolled of which 32 were evaluable for response and toxicity. Estradiol suppression was assessed, with mean estradiol levels of 18.7 pg/mL at 3 months and 14.8 pg/mL at 6 months. One participant (3.1%) experienced a complete response, 11 (34.4%) experienced partial response, and 11 (34.4%) experienced stable disease for 6 months or longer for a clinical benefit rate of 71.9%. Median time to progression was 8.3 months (range, 2.1 to 63+) and median survival was not been reached (range, 11.1 to 63+). The most common adverse events were fatigue (50%), arthralgias (53%), and hot flashes (59%). There were no grade 4 to 5 toxicities. Conclusion The combination of goserelin plus anastrozole has substantial antitumor activity in the treatment of premenopausal women with hormone receptor–positive metastatic breast cancer.

A Phase II Trial of Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer Who Have Received Prior Taxane Therapy

2010 ◽  
Vol 10 (2) ◽  
pp. 148-153 ◽  
Author(s):  
John Pippen ◽  
Anthony D. Elias ◽  
Marcus Neubauer ◽  
Christopher Stokoe ◽  
LaTrice G. Vaughn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Breast

A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer

2010 ◽  
Vol 28 (8) ◽  
pp. 865-871 ◽  
Author(s):  
Denise A. Yardley ◽  
Davey Daniel ◽  
Michael Stipanov ◽  
D. Randolph Drosick ◽  
Mark Mainwaring ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
Her2 Positive

Phase II Trial of Weekly Vinorelbine and Trastuzumab as First‐Line Therapy in Patients with HER2 + Metastatic Breast Cancer

2002 ◽  
Vol 7 (5) ◽  
pp. 410-417 ◽  
Author(s):  
Mohammad Jahanzeb ◽  
Joanne E. Mortimer ◽  
Furhan Yunus ◽  
David H. Irwin ◽  
James Speyer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer

2006 ◽  
Vol 25 (1) ◽  
pp. 63-67 ◽  
Author(s):  
Neelima Denduluri ◽  
James J. Lee ◽  
Janice Walshe ◽  
Arlene W. Berman ◽  
Ujala Vatas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
Epothilone B
Sign in / Sign up

Export Citation Format

Share Document